![HM Logo[words].jpg](https://static.wixstatic.com/media/f6e04a_f429f6c8934d4e4c9e79fcf44a95a0ff~mv2.jpg/v1/crop/x_15,y_114,w_628,h_360/fill/w_94,h_48,al_c,q_80,usm_0.66_1.00_0.01,enc_avif,quality_auto/HM%20Logo%5Bwords%5D.jpg){kind=small}
PHASE 1 COMPLETE · CLINICAL STAGE BIOPHARMACEUTICAL
Haoma Medica is developing Naquinate — a first-in-class vitamin K derivative and the only naturally-occurring compound that regulates both bone build-up and bone breakdown without side effects. A smart, oral, non-toxic alternative to bisphosphonates for the 500 million people living with osteoporosis.
Working with the body to rebuild bone.
ABOUT HAOMA MEDICA
A purpose-built biotech targeting the world's most under-treated bone disease.
Who We Are
Haoma Medica is a UK-based clinical-stage biopharmaceutical company founded to develop NaQuinate — a first-in-class, naturally derived vitamin K analogue — into an approved therapeutic for osteoporosis and related bone diseases. Founded by Prof. Stephen Hodges, Dr. Cenk Oguz and Carmen Greco, our team combines world-class academic science with deep clinical and commercial expertise.
Our Mission
To bring a safe, orally-administered, novel treatment to the 500 million people suffering from osteoporosis globally — with particular focus on those for whom current therapies are inadequate, unsafe, or inaccessible.
Our Philosophy
Existing osteoporosis drugs work against the body — freezing bone turnover and accumulating toxicity over time. NaQuinate is different: it is a smart drug that works with the body's own remodelling response to weight-bearing exercise, supporting bone formation where it is needed without disabling natural repair pathways.
Academic Foundation
Our scientific programme is grounded in longstanding collaboration with The Royal Veterinary College, London, Tromsø University Hospital, and a network of internationally recognised advisors in bone metabolism, endocrinology, and clinical pharmacology.
STATISTICS
Osteoporosis: a global crisis hiding in plain sight.
Osteoporosis causes more than 31 million fractures annually worldwide — one every single second. Yet more than 80% of at-risk individuals remain undiagnosed and untreated. Existing therapies carry significant side effects and compliance challenges.
THE SCIENCE
Discovered at the Royal Veterinary College, London.
NaQuinate was discovered and developed by Prof. Stephen Hodges during collaborative research at the Royal Veterinary College. The compound is a synthetic derivative of vitamin K2 (menaquinone-7), engineered to maximise therapeutic bone activity while retaining the favourable safety profile of its parent compound.
The compound is covered by a robust intellectual property portfolio and has successfully progressed through chemical synthesis, in vitro biological activity characterisation, and two independent in vivo murine models of osteoporosis — demonstrating significant bone-protective effects in both models. Recent mechanistic work points to Wnt16-mediated β-catenin activation as a key driver of NaQuinate's anabolic bone effect.
- Phase I first-in-human trial completed — no significant safety or tolerability concerns
- Demonstrated bone-protective efficacy in two independent murine osteoporosis models
- One granted patent covering UK, US, Canada, Australia, Japan, India, China, Brazil, Israel and the European zone
- 70+ peer-reviewed publications from the Haoma scientific team
- Active collaboration with UCB, Royal Veterinary College, UCL and Tromsø University Hospital
- Novel mechanism of action distinct from all currently approved osteoporosis therapies
MECHANISM OF ACTION
Naquinate. The only supplement that regulates both sides of bone remodelling.
A unique mechanism of dual action that occurs naturally within the body — Nq8 acts as a modulator of the constant regeneration cycle that maintains bone health, working directly on the two key bone cells.
01 Inhibits Osteoclasts
Suppresses the bone-resorbing cells that drive age-related bone loss — slowing the breakdown of existing bone tissue.
02 Promotes Osteoblasts
Simultaneously stimulates the cells that form new bone — restoring the formation/resorption balance disrupted in osteoporosis.
ESTABLISHED PATHWAYS MODULATED BY Nq8
OPG/RANKL
Wnt 16 / β-catenin
Modulates osteoprotegerin (OPG) — the OPG/RANKL pathway is a recognised and established pathway in the bone remodelling process, controlling osteoclasts.
Modulates Wnt 16 — the Wnt 16/β-catenin pathway is a recognised and established pathway in the bone remodelling process, controlling osteoblasts.
STRENGTHS OF NAQUINATE
Nq8 inhibits bone loss in a pharmaceutical industry “Gold Standard” animal model of postmenopausal osteoporosis. The market is ready for a novel treatment with a new mechanism of action for managing patients at risk of fracture, one that addresses the unmet need for a therapy with greater efficacy in treating and preventing long-bone fractures, with a better safety profile. We believe NaQuinate and Osteopura can meet these requirements.
-
Novel class of compound
-
Unique mechanism of action
-
A product naturally occurring in the body
-
Small molecule
-
Low dosage administered orally
Our products combine our novel bioactive ingredient Naquinate- Nq8 with a unique combination of ingredients that have been carefully formulated by our two founders, consultant orthopaedic surgeon Dr Cenk Oguz and bone health scientist Dr Stephen Hodges.
SCIENCE
Why existing drugs fail patients.
Every approved osteoporosis therapy treats one side of bone biology — either resorption or formation. They are expensive, carry significant side effects, and are abandoned by most eligible patients. Anti-resorptive agents deliver only ~20% anti-fracture efficacy with little or no cortical effect.
THE EVIDENCE
Preclinical data confirm the dual mechanism in vivo.
Both bone formation and bone strength increased in osteopenia and osteoporosis prevention models. The long limb bone (tibia) showed both expansion and positive change in thickness — and cortical effects were confirmed along the whole length of bone in repeat studies.
01
02
03
04
Cortical bone strengthened — long-term treatment increased cortical thickness and bone mineral density in the long limb bone.
Trabecular bone protected — short-term treatment (6 weeks) at 250 µg/Kg seen to protect trabecular bone in the proximal tibia.
Repeat study confirmed — cortical effects validated along the whole length of the long limb bone.
Dual modality observed — formation increased and resorption suppressed, consistent with mechanism.
THE OSTEOPENIC WINDOW
Affecting 40% of adults — a diagnostic gap between healthy and diseased, clinically real and almost no one is treated.
TEAM
Naquinate, Nq8 Better bone health, scientifically formulated.
A new and unique combination of bone health supplements built around the novel dual bone action ingredient Nq8 — designed to strengthen bones, support normal density, minimise bone loss, prevent calcium build-up in arteries, and defend against fractures.
01 Complementary Ingredients
Carefully formulated synergy of cofactors that amplify Nq8 mechanism.
02 GMP Manufacture
Pharmaceutical-grade manufacturing under Good Manufacturing Practice.
03 Clean Labelling
No fillers, no animal by-products. Vegan, Kosher, Halal certified.
04 Sustainable Products
Plastic-free packaging and ingredient transparency throughout the supply chain.
05 Patent Protection
Supported by Haoma Medica's global patent portfolio covering composition and use
MANUFACTURING
Pharmaceutical rigour applied to a nutraceutical supply chain.
TEAM
World-class expertise in bone science, clinical development & finance.
PRESS
News & Announcements
Phase I First-in-Human Trial of NaQuinate Completed — No Significant Safety or Tolerability Concerns
INVESTMENT ROUND OPEN
Investment round open — Naquinate & Osteopura+
Haoma Medica is raising an Investment round to launch the Naquinate consumer brand and its flagship Osteopura+ nutraceutical, generating near-term revenue alongside the continued clinical development of NaQuinate. Phase I is complete with no significant safety or tolerability concerns; Phase II is in design.
First in Class Asset
NaQuinate represents a genuinely novel mechanism of action for osteoporosis — distinct from every currently approved therapeutic. First-mover advantage in a $17B and growing market with unmet need at its core.
Robust IP Portfolio
One granted patent covering composition of matter, synthesis routes and therapeutic applications of NaQuinate, with global jurisdictional coverage — providing strong exclusivity and significant licensing potential across multiple therapeutic indications beyond osteoporosis.
De-Risk Pofile
Phase I human trial complete with no significant safety or tolerability concerns; PK and exploratory PD data presented at ASBMR 2022. Robust pre-clinical and regulatory toxicology package via accredited CROs. Derived from naturally occurring vitamin K.
World Class Professionals
Our executive and advisory team spans Goldman Sachs, Johnson & Johnson, University College London, Imperial College, and the UK NHS — bringing together the commercial acumen, scientific depth, and clinical expertise required to succeed.
Multiple Paths
Osteopura is ideal for out-licensing to a major pharmaceutical partner following Phase II proof-of-concept, or as a full acquisition target. The global bone therapeutics market is active with established pharmaceutical company acquirers.
Commercial Path
The Naquinate nutraceutical division — led by flagship Osteopura+ — is the focus of the current Investment raise. It generates commercial revenue, brand equity and consumer market intelligence, supporting operations while clinical development advances and reducing dependency on equity financing alone.